© 1994 Oxford University Press
OTHER |
Genetic heterogeneity in familial malignant melanoma
ICRF Human Genetic Resources Laboratory, Clare Hall Laboratories South Mimms, Herts EN6 3LD 1ICRF Skin Tumour Laboratory, Royal London Hospital Whitechapel, London E1 1BB 2ICRF Genebc Eptdemiotogy Laboratory, St Jamess Hospital Leeds LS9 7TF 3ICRF Molecular Analysis of Mammalian Mutation Laboratory 4ICRF Mathematics, Statistics and Epidemiology Laboratory Lincolns Inn Reids, London WC2A 3PX, UK 5CNRS, Laboratoire de Genetique Moteculaire, 1 Avenue de la Terrasse 91198 Gif-sur-Yvette, France
*To whom correspondence should be addressed
Following reports of linkage to chromosome 9p In families with malignant melanoma, we have been studying a series of UK families. Six families were selected with three or more cases of malignant melanoma. We have used a total of twelve markers mapping In the Interval 9p13p23 and constructed a set of haplotypes to study the Inheritance of the disease chromosome. Of the six families, three were consistent with linkage to the short arm of 9, although their limited size precluded confirmation of linkage. One family was clearly unlinked, one family was either unlinked, or contains a sporadic case, or delimits the location of the melanoma gene, and one family was essentially unlnformative. This Is strong evidence for genetic heterogeneity In families with the malignant melanoma phenotype. We have also sequenced exon 2 of the recently identified candidate tumour suppressor gene, p16, in six Individuals and found no evidence for germline mutations In this region of the p16 gene In our families with Inherited malignant melanoma.
+Present address: Department of Dermatology, St George's Hospital, London, Blackshaw Road, London SW17, UK
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. J. Huot, J. Rowe, M. Harland, S. Drayton, S. Brookes, C. Gooptu, P. Purkis, M. Fried, V. Bataille, E. Hara, et al. Biallelic Mutations in p16INK4a Confer Resistance to Ras- and Ets-Induced Senescence in Human Diploid Fibroblasts Mol. Cell. Biol., December 1, 2002; 22(23): 8135 - 8143. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. te Poele, A. L. Okorokov, L. Jardine, J. Cummings, and S. P. Joel DNA Damage Is Able to Induce Senescence in Tumor Cells in Vitro and in Vivo Cancer Res., March 1, 2002; 62(6): 1876 - 1883. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Tucker, A. Halpern, E. A. Holly, P. Hartge, D. E. Elder, R. W. Sagebiel, D. Guerry IV, and W. H. Clark Jr Clinically Recognized Dysplastic Nevi: A Central Risk Factor for Cutaneous Melanoma JAMA, May 14, 1997; 277(18): 1439 - 1444. [Abstract] [PDF] |
||||
![]() |
A. M. Goldstein, M. C. Fraser, J. P. Struewing, C. J. Hussussian, K. Ranade, D. P. Zametkin, L. S. Fontaine, S. M. Organic, N. C. Dracopoli, W. H. Clark, et al. Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds with p16INK4 Mutations N. Engl. J. Med., October 12, 1995; 333(15): 970 - 975. [Abstract] [Full Text] [PDF] |
||||



